Melissa J Armstrong1, Gary S Gronseth2, Gregory S Day3, Carol Rheaume4, Slande Alliance1, C D Mullins5. 1. Department of Neurology, McKnight Brain Institute, University of Florida College of Medicine, Gainesville, FL. 2. Department of Neurology, University of Kansas Medical Center, Kansas City, KS. 3. Department of Neurology, The Charles F and Joanne Knight Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, MO. 4. American Academy of Neurology, Minneapolis, MN. 5. Pharmaceutical Health Research Department, University of Maryland School of Pharmacy, Baltimore, MD.
Abstract
BACKGROUND: Patient and caregiver perspectives on amyloid positron emission tomography (PET) use are largely unexplored, particularly as compared with clinician views. METHODS: We surveyed clinicians, patients, caregivers, and dementia advocates on topics relating to an evidence-based guideline on amyloid PET use. Topic importance was rated on a 9-point scale. Patient stakeholder and clinician views were compared using the Mann-Whitney U test. RESULTS: Patient representatives (n=107) rated all survey topics as equal to or more important than clinicians (n=114) except 1 item discussing potential harms of false-positive diagnoses. Differences between patient representative and clinician populations were greatest when comparing the competing values of false-positive and false-negative diagnoses and the value of testing asymptomatic individuals. CONCLUSIONS: Patients and caregivers emphasized the importance of having a dementia diagnosis and placed more value on testing and outcomes for asymptomatic populations than clinicians. This underscores the importance of research investigating the effect of amyloid PET results on asymptomatic individuals and the need for amyloid PET ordering and disclosure standards.
BACKGROUND:Patient and caregiver perspectives on amyloid positron emission tomography (PET) use are largely unexplored, particularly as compared with clinician views. METHODS: We surveyed clinicians, patients, caregivers, and dementia advocates on topics relating to an evidence-based guideline on amyloid PET use. Topic importance was rated on a 9-point scale. Patient stakeholder and clinician views were compared using the Mann-Whitney U test. RESULTS:Patient representatives (n=107) rated all survey topics as equal to or more important than clinicians (n=114) except 1 item discussing potential harms of false-positive diagnoses. Differences between patient representative and clinician populations were greatest when comparing the competing values of false-positive and false-negative diagnoses and the value of testing asymptomatic individuals. CONCLUSIONS:Patients and caregivers emphasized the importance of having a dementia diagnosis and placed more value on testing and outcomes for asymptomatic populations than clinicians. This underscores the importance of research investigating the effect of amyloid PET results on asymptomatic individuals and the need for amyloid PET ordering and disclosure standards.
Authors: Gordon H Guyatt; Andrew D Oxman; Regina Kunz; David Atkins; Jan Brozek; Gunn Vist; Philip Alderson; Paul Glasziou; Yngve Falck-Ytter; Holger J Schünemann Journal: J Clin Epidemiol Date: 2010-12-30 Impact factor: 6.437
Authors: Jeffrey M Burns; David K Johnson; Edward P Liebmann; Rebecca J Bothwell; Jill K Morris; Eric D Vidoni Journal: Alzheimers Dement Date: 2017-03-03 Impact factor: 21.566
Authors: Arno de Wilde; Wiesje M van der Flier; Wiesje Pelkmans; Femke Bouwman; Jurre Verwer; Colin Groot; Marieke M van Buchem; Marissa Zwan; Rik Ossenkoppele; Maqsood Yaqub; Marleen Kunneman; Ellen M A Smets; Frederik Barkhof; Adriaan A Lammertsma; Andrew Stephens; Erik van Lier; Geert Jan Biessels; Bart N van Berckel; Philip Scheltens Journal: JAMA Neurol Date: 2018-09-01 Impact factor: 18.302
Authors: Karen E Mate; Constance D Pond; Parker J Magin; Susan M Goode; Patrick McElduff; Nigel P Stocks Journal: Int Psychogeriatr Date: 2012-07-04 Impact factor: 3.878
Authors: Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling Journal: Alzheimers Dement Date: 2018-04 Impact factor: 21.566
Authors: Fred B Ketchum; Claire M Erickson; Nathaniel A Chin; Carey E Gleason; Nickolas H Lambrou; Susan Flowers Benton; Lindsay R Clark Journal: J Alzheimers Dis Date: 2022 Impact factor: 4.160